JPWO2022078357A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022078357A5 JPWO2022078357A5 JP2023523084A JP2023523084A JPWO2022078357A5 JP WO2022078357 A5 JPWO2022078357 A5 JP WO2022078357A5 JP 2023523084 A JP2023523084 A JP 2023523084A JP 2023523084 A JP2023523084 A JP 2023523084A JP WO2022078357 A5 JPWO2022078357 A5 JP WO2022078357A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- cdr1
- seq
- nos
- acid sequences
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2020/120918 | 2020-10-14 | ||
| CN2020120918 | 2020-10-14 | ||
| CNPCT/CN2021/085335 | 2021-04-02 | ||
| CN2021085335 | 2021-04-02 | ||
| PCT/CN2021/123438 WO2022078357A1 (en) | 2020-10-14 | 2021-10-13 | Anti-pd-1/cd40 bispecific antibodies and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023545521A JP2023545521A (ja) | 2023-10-30 |
| JPWO2022078357A5 true JPWO2022078357A5 (enExample) | 2024-10-24 |
Family
ID=81207517
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023523084A Pending JP2023545521A (ja) | 2020-10-14 | 2021-10-13 | 抗ｐｄ－１／ｃｄ４０二重特異性抗体及びその使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230220082A1 (enExample) |
| EP (1) | EP4229096A4 (enExample) |
| JP (1) | JP2023545521A (enExample) |
| KR (1) | KR20230092932A (enExample) |
| CN (1) | CN116390755A (enExample) |
| AU (1) | AU2021359495A1 (enExample) |
| BR (1) | BR112023006989A2 (enExample) |
| CA (1) | CA3197463A1 (enExample) |
| IL (1) | IL302042A (enExample) |
| MX (1) | MX2023004275A (enExample) |
| WO (1) | WO2022078357A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117624372A (zh) * | 2022-08-26 | 2024-03-01 | 北京天广实生物技术股份有限公司 | 靶向cd40和pd-l1的抗体及其用途 |
| CN116023495B (zh) * | 2022-09-05 | 2023-10-03 | 上海百英生物科技股份有限公司 | 一种抗cd40纳米抗体及其制备方法与应用 |
| CN119894928A (zh) * | 2022-09-20 | 2025-04-25 | 科锐生物制品私人有限公司 | 拯救耗竭的免疫细胞的方法 |
| JP2026501724A (ja) * | 2023-01-06 | 2026-01-16 | アプティーボ リサーチ アンド デベロップメント エルエルシー | 二重特異性ｐｄ－ｌ１及びｃｄ４０結合分子ならびにその使用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3534951A4 (en) * | 2016-11-02 | 2020-09-23 | Apexigen, Inc. | ANTI-CD40 ANTIBODIES IN COMBINATION AND METHOD OF USES |
| JP7110369B2 (ja) * | 2018-02-23 | 2022-08-01 | ユーキュア・（ベイジン）・バイオファーマ・カンパニー・リミテッド | 抗ｐｄ－１抗体及びその用途 |
| KR102728939B1 (ko) * | 2018-07-20 | 2024-11-11 | 유큐(베이징) 바이오파마 코., 엘티디 | 항-cd40 항체 및 그의 용도 |
| WO2020102233A1 (en) * | 2018-11-13 | 2020-05-22 | Jn Biosciences Llc | Bispecific antibodies for activation of immune cells |
| CA3158527A1 (en) * | 2019-10-23 | 2021-04-29 | Lyvgen Biopharma Holdings Limited | Anti-cd40 binding molecules and bi-specific antibodies comprising such |
-
2021
- 2021-10-13 KR KR1020237014700A patent/KR20230092932A/ko active Pending
- 2021-10-13 WO PCT/CN2021/123438 patent/WO2022078357A1/en not_active Ceased
- 2021-10-13 IL IL302042A patent/IL302042A/en unknown
- 2021-10-13 CA CA3197463A patent/CA3197463A1/en active Pending
- 2021-10-13 JP JP2023523084A patent/JP2023545521A/ja active Pending
- 2021-10-13 MX MX2023004275A patent/MX2023004275A/es unknown
- 2021-10-13 BR BR112023006989A patent/BR112023006989A2/pt unknown
- 2021-10-13 AU AU2021359495A patent/AU2021359495A1/en active Pending
- 2021-10-13 CN CN202180069673.0A patent/CN116390755A/zh active Pending
- 2021-10-13 EP EP21879400.6A patent/EP4229096A4/en active Pending
-
2023
- 2023-01-05 US US18/150,428 patent/US20230220082A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Wang et al. | The state of the art of bispecific antibodies for treating human malignancies | |
| Jin et al. | Emerging new therapeutic antibody derivatives for cancer treatment | |
| Wei et al. | Current landscape and future directions of bispecific antibodies in cancer immunotherapy | |
| Bathula et al. | Nanobodies: the future of antibody-based immune therapeutics | |
| Wu et al. | Recent advances and challenges of bispecific antibodies in solid tumors | |
| JP2021501162A5 (enExample) | ||
| RU2573893C2 (ru) | Фармацевтические композиции с устойчивостью к растворимому сеа | |
| KR102757960B1 (ko) | 간세포암(hepatocellular carcinoma: HCC)에 대한 면역 치료 | |
| JP2020147572A (ja) | リンパ球における阻害経路の中和 | |
| JP6608698B2 (ja) | Ｐ２ｘ７受容体アンタゴニスト及びアゴニスト | |
| JP2021529741A (ja) | がん治療 | |
| JP2018536632A5 (ja) | Ｂ７‐ｈ３に特異的に結合する分子及びｐｄ‐１に特異的に結合する分子 | |
| TWI908743B (zh) | 抗dll3藥劑之給藥方案 | |
| US20250034273A1 (en) | Composition of multispecific antibodies targeting cadherin-17-expressing tumors and method of making and using thereof | |
| JP2024518200A (ja) | Ｔ細胞リダイレクト治療薬及び抗ｃｄ４４治療薬を含む組成物 | |
| Guo et al. | Revolutionizing cancer immunotherapy: unleashing the potential of bispecific antibodies for targeted treatment | |
| Wu et al. | A humanized trivalent Nectin-4-targeting nanobody drug conjugate displays potent antitumor activity in gastric cancer | |
| JP2025508066A (ja) | 目的としたｔ細胞活性化のためのｃｄ２８二重特異性抗体 | |
| Chen | Conditionally active T cell engagers for the treatment of solid tumors: rationale and clinical development | |
| Valent et al. | Cell-based and antibody-mediated immunotherapies directed against leukemic stem cells in acute myeloid leukemia: perspectives and open issues | |
| Arnett et al. | IBC's 21st Annual Antibody Engineering and 8th Annual Antibody Therapeutics International Conferences and 2010 Annual Meeting of The Antibody Society: December 5–9, 2010, San Diego, CA USA | |
| Jachimowicz et al. | Multi-specific antibodies for cancer immunotherapy | |
| Yuan et al. | Characterization of a novel T cell-engaging bispecific antibody for elimination of L1CAM-positive tumors | |
| JPWO2022078357A5 (enExample) | ||
| Heidari et al. | The potential of monoclonal antibodies for colorectal cancer therapy |